Amphotericin B (Fungizone)

Amphotericin B, marketed under the brand name Fungizone among others, is a powerful polyene antifungal antibiotic that serves as a critical treatment option for serious fungal infections in horses. Derived from the bacterium Streptomyces nodosus, amphotericin B has been used in medicine since the 1950s and remains one of the most effective antifungal agents available for treating life-threatening mycotic diseases. In equine medicine, this medication plays an essential role in managing conditions including guttural pouch mycosis, fungal keratitis, and systemic fungal infections that may not respond adequately to other antifungal therapies.

The mechanism of action of amphotericin B involves binding to ergosterol, a fundamental component of fungal cell membranes that is not found in mammalian cells. This binding creates pores in the fungal cell membrane, leading to leakage of essential cellular contents and ultimately fungal cell death. The preferential binding to ergosterol over cholesterol, the analogous component in mammalian cell membranes, provides the basis for selective antifungal activity. However, some binding to mammalian cell membranes does occur, which accounts for the drug's significant toxicity profile and necessitates careful monitoring during therapy.

Amphotericin B is available in several formulations for equine use, including conventional amphotericin B deoxycholate and lipid-based formulations that may offer improved safety profiles. The drug can be administered intravenously for systemic infections, applied topically for localized fungal conditions, instilled directly into the guttural pouch for mycosis, or formulated for ophthalmic use in treating fungal keratitis. Regional limb perfusion may be employed for fungal infections of the distal limb. The route of administration depends on the location and severity of infection, with the veterinarian selecting the approach most likely to achieve therapeutic concentrations at the site of infection.

Due to the serious nature of conditions requiring amphotericin B treatment and the significant potential for adverse effects, this medication requires careful veterinary supervision throughout the treatment course. Comprehensive patient evaluation before treatment, close monitoring during therapy, and appropriate supportive care all contribute to successful outcomes. The decision to use amphotericin B involves weighing the severity of the fungal infection against the risks of treatment, and this potent antifungal is typically reserved for serious infections where other treatments have failed or are unlikely to succeed.

Guttural pouch mycosis represents one of the most critical indications for amphotericin B in equine medicine. This serious fungal infection, typically caused by Aspergillus species, affects the guttural pouches and can erode into major blood vessels including the internal carotid artery, potentially causing life-threatening hemorrhage. Amphotericin B may be administered directly into the affected guttural pouch through catheterization, providing high local concentrations at the site of infection. This localized therapy approach helps manage the infection while minimizing systemic exposure and toxicity. Treatment often requires multiple instillations over several weeks, combined with other interventions as determined by the treating veterinarian.

Fungal keratitis, a serious infection of the cornea that can lead to vision loss or loss of the eye, is commonly treated with topical amphotericin B in horses. This condition often occurs following corneal trauma or ulceration, particularly in humid environments or when corticosteroid medications have been used. The most common causative organisms include Aspergillus and Fusarium species. Topical amphotericin B solution, typically compounded specifically for ophthalmic use, is applied frequently to the affected eye to achieve fungicidal concentrations in the corneal tissues. Treatment duration often extends several weeks to months, requiring significant owner commitment and close veterinary monitoring to assess response and detect complications.

Systemic fungal infections, though relatively uncommon in horses, may require treatment with intravenous amphotericin B when other antifungal agents are ineffective or when the causative organism is known to be susceptible primarily to this drug. Systemic aspergillosis, candidiasis, and infections caused by other susceptible fungi may warrant amphotericin B therapy. Immunocompromised horses, including those with severe concurrent illness or those receiving immunosuppressive medications, may be particularly susceptible to systemic fungal infections. The decision to use systemic amphotericin B carefully considers the severity of infection, the organism involved, and the significant toxicity associated with intravenous administration.

Regional limb perfusion with amphotericin B may be employed for fungal infections affecting the distal limb structures, including synovial structures, bones, or soft tissues. This technique delivers high local drug concentrations while minimizing systemic exposure. Fungal arthritis, osteomyelitis, or soft tissue infections of the lower limb that are refractory to other treatments may benefit from this approach. The procedure requires specialized training and equipment and is performed under controlled conditions with appropriate monitoring.

Other localized fungal infections may be treated with topical amphotericin B formulations or intralesional injection depending on the site and nature of the infection. Cutaneous fungal infections that have not responded to standard topical antifungals may occasionally warrant amphotericin B therapy. The veterinarian evaluates each case individually to determine whether amphotericin B treatment is appropriate and which route of administration will provide optimal results for the specific infection being treated.

Dosing protocols for amphotericin B in horses are determined by the veterinarian based on the specific condition being treated, the route of administration, and individual patient factors. Due to the significant toxicity potential and the serious nature of infections requiring this medication, treatment is typically conducted under close veterinary supervision or in a hospital setting for systemic therapy. Accurate patient assessment, baseline laboratory evaluation, and ongoing monitoring are essential components of safe amphotericin B therapy.

Intravenous amphotericin B administration requires careful attention to preparation, dilution, and infusion protocols. The conventional formulation must be diluted in dextrose solution rather than saline, as electrolytes can cause precipitation. Infusion is administered slowly over several hours to minimize acute reactions. Dosing typically begins at lower levels and gradually increases as tolerated, with the specific protocol determined by the treating veterinarian. The total cumulative dose is monitored to minimize the risk of nephrotoxicity, and treatment continues until adequate clinical response is achieved or toxicity limits further therapy.

Guttural pouch instillation for mycosis treatment involves catheterization of the affected pouch and direct infusion of amphotericin B solution. The concentration and volume administered are determined by the veterinarian based on the extent of infection and the size of the guttural pouch. Treatments are typically repeated at regular intervals, often every one to three days, for a total course lasting several weeks. The procedure requires appropriate restraint and may be performed under sedation. Endoscopic evaluation of the guttural pouch helps assess treatment response and guides decisions about treatment duration.

Ophthalmic administration for fungal keratitis involves frequent application of amphotericin B solution to the affected eye. Initial treatment often requires application every one to two hours around the clock, with frequency gradually decreasing as the infection responds. Treatment duration typically extends four to six weeks or longer, depending on the depth and extent of corneal involvement. Subpalpebral lavage systems may be placed to facilitate frequent medication administration and reduce handling stress for the horse. Close ophthalmic monitoring ensures treatment adequacy and enables early detection of complications.

Regional limb perfusion delivers amphotericin B directly to distal limb structures through isolation of the regional blood supply and infusion of medicated solution. The procedure requires appropriate sedation, tourniquet placement, and sterile technique. The specific dose and concentration are determined by the veterinarian based on the infection being treated. Repeat perfusions may be necessary at intervals determined by clinical response. The horse should be monitored for local reactions and any signs of systemic effects following the procedure.

Treatment completion depends on clinical and, where applicable, laboratory evidence of infection resolution. For serious fungal infections, premature discontinuation risks treatment failure and relapse. However, cumulative toxicity may limit total treatment duration, requiring the veterinarian to balance therapeutic goals against safety considerations. Follow-up evaluation after treatment completion helps ensure the infection has resolved and enables early detection of any recurrence.

Amphotericin B is associated with significant potential adverse effects that require careful patient selection, thorough monitoring, and appropriate supportive care during treatment. Understanding these potential complications enables optimal patient management and early intervention when problems develop. The serious nature of conditions requiring amphotericin B therapy often justifies accepting considerable treatment-related risk, but informed decision-making requires honest assessment of both benefits and potential harms.

Nephrotoxicity represents the most clinically significant systemic adverse effect of amphotericin B therapy. The drug causes dose-dependent kidney damage that can range from mild, reversible renal impairment to severe, permanent kidney failure. Manifestations include decreased urine production, elevated blood urea nitrogen and creatinine, electrolyte imbalances, and in severe cases, acute renal failure requiring supportive care. Baseline renal function assessment and regular monitoring during therapy enable early detection of nephrotoxicity. Strategies to minimize kidney damage include adequate hydration, sodium loading in some protocols, and careful attention to cumulative dosing.

Acute infusion-related reactions may occur during or shortly after intravenous amphotericin B administration. These reactions can include fever, chills, rigors, headache, nausea, and hypotension. In horses, signs may include restlessness, sweating, muscle fasciculations, and cardiovascular changes. Pre-treatment with anti-inflammatory medications may help reduce the severity of these reactions. Slow infusion rates and appropriate dilution are essential for minimizing acute toxicity. Any severe reaction requires immediate cessation of infusion and appropriate supportive treatment.

Electrolyte disturbances occur commonly with amphotericin B therapy, particularly with systemic administration. Hypokalemia and hypomagnesemia result from drug-induced renal tubular damage affecting ion transport. These electrolyte abnormalities can cause muscle weakness, cardiac arrhythmias, and other complications. Regular monitoring of electrolyte levels during treatment enables timely supplementation to maintain normal values. Potassium and magnesium supplementation may be required throughout the treatment course and for a period after treatment completion.

Local tissue reactions occur with various routes of amphotericin B administration. Intravenous infusion can cause phlebitis and venous irritation at the catheter site. Intralesional injection or regional perfusion may cause local tissue reaction. Ophthalmic administration can cause temporary stinging, irritation, and chemosis. Guttural pouch instillation may cause local inflammation that is generally self-limiting. Proper technique and appropriate formulations help minimize local reactions. Severe local reactions should be reported to the veterinarian for evaluation and potential treatment modification.

Known hypersensitivity to amphotericin B or any component of the formulation represents an absolute contraindication to treatment. Although true allergic reactions are uncommon, any history of severe adverse reaction to amphotericin B should preclude future use unless no alternative exists for a life-threatening infection and the potential benefits clearly outweigh the risks. Cross-reactivity between different amphotericin B formulations may occur, and caution is warranted when considering any polyene antifungal in a patient with prior amphotericin B hypersensitivity.

Pre-existing renal impairment significantly increases the risk of amphotericin B nephrotoxicity and may contraindicate therapy or require substantial dose modifications. Horses with elevated blood urea nitrogen or creatinine, decreased urine specific gravity, or other evidence of kidney dysfunction require careful evaluation before amphotericin B treatment is considered. The decision to proceed depends on the severity of renal impairment, the life-threatening nature of the fungal infection, and the availability of alternative treatments. Enhanced monitoring and supportive measures are essential if treatment proceeds in renally compromised patients.

Concurrent administration of other nephrotoxic agents compounds the risk of kidney damage and may contraindicate amphotericin B therapy or require discontinuation of the concurrent medication. Non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics, and other nephrotoxic medications should be avoided when possible during amphotericin B therapy. If concurrent nephrotoxic therapy cannot be avoided, intensive monitoring and supportive measures are essential. The veterinarian evaluates the overall treatment plan to minimize combined nephrotoxic exposure.

Severe electrolyte imbalances, particularly uncorrected hypokalemia or hypomagnesemia, increase the risk of cardiac and neuromuscular complications during amphotericin B therapy. Electrolyte abnormalities should be corrected before initiating treatment when possible. Underlying conditions causing ongoing electrolyte losses may complicate therapy and require intensive monitoring and supplementation. Cardiac arrhythmias associated with electrolyte disturbances may be exacerbated by amphotericin B treatment, and underlying cardiac disease warrants careful consideration before therapy. The overall health status of the patient influences the decision to proceed with treatment and the intensity of monitoring required.

Nephrotoxic medications interact dangerously with amphotericin B due to additive kidney toxicity. Aminoglycoside antibiotics including gentamicin and amikacin are particularly concerning, as both drug classes independently cause significant renal damage. Non-steroidal anti-inflammatory drugs can also contribute to nephrotoxicity and should be used cautiously if at all during amphotericin B therapy. Cyclosporine and other immunosuppressive agents with nephrotoxic potential compound the risk of kidney damage. When concurrent use of nephrotoxic medications cannot be avoided, enhanced renal monitoring and supportive measures are essential.

Corticosteroids may potentiate the hypokalemia caused by amphotericin B, increasing the risk of cardiac arrhythmias and neuromuscular effects. If corticosteroid therapy is necessary during amphotericin B treatment, close monitoring of potassium levels and aggressive supplementation may be required. The combination should be avoided when possible, but the clinical situation may necessitate concurrent use with appropriate safeguards. Mineralocorticoid effects of some corticosteroids may partially offset potassium losses, but this should not be relied upon to prevent significant hypokalemia.

Digoxin and other cardiac glycosides have increased toxicity risk when amphotericin B-induced hypokalemia and hypomagnesemia are present. Low potassium and magnesium levels enhance the cardiac effects of digitalis preparations, potentially causing dangerous arrhythmias. If concurrent use is necessary, meticulous electrolyte monitoring and supplementation are required. The veterinarian may need to adjust cardiac medication doses based on electrolyte status during amphotericin B therapy.

Antifungal azole medications including fluconazole and itraconazole may have antagonistic effects when combined with amphotericin B in some circumstances. Azoles inhibit ergosterol synthesis, potentially reducing the target for amphotericin B binding. However, this theoretical antagonism does not always translate to clinical treatment failure, and combination therapy may be beneficial in some situations. The decision to combine antifungal agents depends on the specific clinical situation, the organisms involved, and the potential benefits of broader coverage or synergistic effects in some fungal infections. Diuretics, particularly loop and thiazide diuretics, may worsen amphotericin B-induced electrolyte abnormalities and volume depletion. If diuretics are medically necessary during treatment, careful attention to fluid and electrolyte status is essential. Potassium-sparing diuretics might help counteract potassium losses but require monitoring to prevent hyperkalemia in the setting of renal dysfunction. The overall fluid and electrolyte management plan should account for the combined effects of all medications.

Comprehensive baseline evaluation before initiating amphotericin B therapy establishes reference values and identifies pre-existing conditions that might affect treatment safety. Complete blood count, serum chemistry profile including renal function and electrolytes, and urinalysis provide essential baseline data. For horses with systemic fungal infections, liver function evaluation may also be warranted. Physical examination findings and patient history help identify factors that might increase treatment risk or require modified monitoring protocols.

Ongoing monitoring during amphotericin B therapy enables early detection of toxicity and guides supportive care interventions. Renal function parameters should be assessed regularly, with frequency depending on the route of administration and total drug exposure. Electrolyte levels, particularly potassium and magnesium, require monitoring throughout treatment and may need supplementation to maintain normal values. Clinical assessment for signs of adverse effects should occur daily during intensive treatment phases. The monitoring protocol is adjusted based on treatment response and any developing complications.

Fluid therapy and supportive care help minimize amphotericin B toxicity and improve treatment tolerance. Adequate hydration before and during intravenous therapy helps protect kidney function. Sodium loading protocols may be employed to reduce nephrotoxicity in some treatment regimens. Electrolyte supplementation addresses losses induced by the medication. Appropriate nutrition and general supportive care maintain patient condition during extended treatment courses. The specific supportive care protocol is tailored to the individual patient and treatment regimen.

Competition horses require awareness that amphotericin B may be considered a prohibited substance under various competition rules, though this is rarely relevant given the serious nature of conditions requiring this medication. Horses receiving amphotericin B for life-threatening conditions are unlikely to be competition candidates during treatment and often require extended recovery periods. Any competition horse that has received amphotericin B should have competition eligibility discussed with the veterinarian and the relevant governing organization before returning to competition.

Human safety considerations apply when handling amphotericin B preparations. The drug is potentially irritating to skin and mucous membranes, and exposure should be minimized through appropriate handling techniques. Gloves should be worn when preparing and administering the medication. Accidental injection or significant exposure warrants medical consultation. Pregnant women should avoid handling amphotericin B due to potential fetal effects. Standard precautions for handling chemotherapy-like agents apply to amphotericin B.

Amphotericin B products require specific storage conditions to maintain stability and potency. Unreconstituted amphotericin B powder should be stored refrigerated at 36 to 46 degrees Fahrenheit and protected from light. The reconstituted solution has limited stability and should be used promptly after preparation or stored according to specific product guidelines. Lipid-based formulations may have different storage requirements than conventional amphotericin B deoxycholate, and product-specific instructions should be followed. Temperature excursions outside the recommended range may affect drug stability and should be avoided.

Preparation of amphotericin B for administration requires attention to specific reconstitution and dilution requirements. The conventional formulation must be reconstituted with sterile water for injection, not saline or other electrolyte-containing solutions. Further dilution uses dextrose in water, as saline causes precipitation. The preparation should be protected from light during storage and administration. Lipid formulations have their own specific preparation requirements that differ from the conventional product. Particulate matter or precipitation in prepared solutions indicates degradation, and such solutions should not be used.

Safe handling practices protect personnel involved in preparing and administering amphotericin B. The drug should be prepared in a clean environment using aseptic technique. Personal protective equipment including gloves and possibly gowns and masks should be worn during preparation to minimize exposure. Spills should be cleaned up carefully using appropriate containment measures. Pregnant healthcare workers should avoid handling this medication. Standard chemotherapy handling precautions provide appropriate guidance for amphotericin B preparation and administration.

Disposal of unused amphotericin B and administration materials should follow appropriate pharmaceutical waste guidelines. Unused medication, contaminated supplies, and administration equipment should be disposed of according to local regulations for pharmaceutical waste. Sharps should be placed in appropriate containers. Environmental contamination with amphotericin B should be avoided through proper disposal practices. Many veterinary facilities have pharmaceutical waste disposal programs that ensure appropriate handling of these materials. Unused medication should never be saved for potential future use, as stability after reconstitution is limited and contamination risk increases with time.

Draft breeds requiring amphotericin B therapy present considerations related to their larger body size and potential differences in drug distribution. Clydesdales, Percherons, Shires, and Belgians may exceed 2,000 pounds, affecting dose calculations for systemic therapy. The larger blood volume and tissue mass of draft breeds influence drug distribution, and dosing protocols must be adjusted accordingly. Accurate weight determination using livestock scales is particularly important for these large patients. The relative frequency of different fungal infections may vary somewhat between draft breeds and lighter horses based on environmental factors and use patterns rather than intrinsic breed susceptibility.

Light horse breeds and warmbloods represent the reference population for most amphotericin B treatment protocols in horses. Thoroughbreds, Quarter Horses, Arabians, and various warmblood breeds typically weigh between 900 and 1,400 pounds and respond predictably to established treatment protocols. Individual variation in drug tolerance exists, and monitoring during therapy helps identify horses that may require protocol modifications. Performance horses within these breed categories face competition considerations, though horses requiring amphotericin B for serious fungal infections are typically not competition candidates during treatment and convalescence.

Ponies and miniature horses require careful dose calculations scaled to their smaller body size. Formulations and doses appropriate for full-sized horses may need adjustment for accurate delivery to small equines. Miniature horses present particular challenges for systemic therapy, as their small size affects drug preparation and administration. The same monitoring principles apply regardless of patient size, with laboratory parameters assessed relative to species and size-appropriate reference ranges. Topical and local administration routes may be relatively more practical for small patients when appropriate for the infection being treated.

Breed-specific disease predispositions do not significantly affect amphotericin B therapy selection, but overall health status influences treatment decisions. Breeds or individuals with predispositions to renal disease require careful evaluation before treatment and enhanced monitoring during therapy. Horses with concurrent health conditions affecting drug tolerance need individualized treatment plans accounting for their overall status. The veterinarian considers the complete patient picture, including breed characteristics and individual health factors, when developing amphotericin B treatment protocols and monitoring plans.

Azole antifungal medications provide alternative systemic antifungal options that may be appropriate for less severe infections or as step-down therapy after initial amphotericin B treatment. Fluconazole offers good bioavailability with oral administration and is commonly used for susceptible fungal infections. Itraconazole provides broader spectrum coverage but has more variable absorption. Voriconazole may be effective against some amphotericin-resistant organisms. These oral medications are generally better tolerated than amphotericin B and may be used for prolonged maintenance therapy after initial disease control is achieved with amphotericin B for serious infections.

Topical antifungal preparations provide options for superficial or localized fungal infections where systemic therapy is not required. Miconazole, clotrimazole, and other topical azoles may effectively treat cutaneous fungal infections. Natamycin is commonly used for equine fungal keratitis as an alternative to topical amphotericin B. The selection of topical antifungal depends on the organism involved, the location and extent of infection, and practical considerations regarding application. For serious corneal infections, multiple topical agents may be used in combination.

Echinocandin antifungals represent a newer class of antifungal agents with mechanisms of action different from both amphotericin B and azoles. Caspofungin and related drugs inhibit fungal cell wall synthesis and may be effective against some organisms resistant to other antifungals. However, experience with these agents in horses is limited, and their role in equine antifungal therapy is not well established. They may be considered for refractory infections when other options have failed, under specialist guidance.

Supportive therapies complement antifungal treatment regardless of the specific agent used. Surgical debridement may be necessary for fungal infections involving devitalized tissue or those refractory to medical management alone. Guttural pouch mycosis may require surgical intervention in addition to topical antifungal therapy, particularly when significant arterial involvement threatens hemorrhage. Keratectomy may be performed for fungal keratitis in selected cases. The overall treatment plan typically combines pharmacological antifungal therapy with appropriate surgical and supportive interventions as indicated by the specific clinical situation. Substitution of antifungal agents should only be done under veterinary guidance, as different drugs have distinct spectra of activity and safety profiles that make them appropriate for different clinical situations.